Peptide Pens

KLOW is a catalogue name commonly used for a four-component research blend of GHK-Cu, BPC-157, TB-500 and KPV. It brings together materials investigated in skin and connective-tissue biology, cell migration and inflammatory signalling. Check the product label and batch documentation for the precise formulation of the supplied pen.

Melanotan II (MT2) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a signal involved in skin pigmentation. It activates melanocortin receptors and is studied for its ability to stimulate melanin, the pigment responsible for skin colour and tanning. A small early human study observed increased pigmentation, but this does not establish long-term safety or validate this pen formulation. Reported effects include nausea, flushing and changes in moles or freckles. This entry identifies the labelled 10 mg pen format. For research purposes only; not an approved tanning treatment or a substitute for sun protection.

A naturally occurring copper-binding tripeptide researched in skin, extracellular-matrix and wound-repair biology. Studies explore collagen, elastin, tissue remodelling and hair-follicle pathways, with evidence varying by formulation and use.

A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research. Studies consider cell migration, inflammatory signalling and wound-repair pathways, but the combined ‘Wolverine’ format is not an approved clinical formulation.

NAD+ (nicotinamide adenine dinucleotide) is a cellular coenzyme involved in oxidation–reduction reactions and energy metabolism. It is not a peptide. The listed strength and presentation identify the catalogue format, not proven bioavailability or an established anti-ageing effect.

A mitochondria-derived peptide studied as a signal connecting cellular stress, energy use and metabolic adaptation. Research explores mitochondrial function, insulin sensitivity and exercise-response pathways, although most intervention evidence remains preclinical.

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways. Authorised prescription versions have established clinical uses, but unlicensed research material is not equivalent to an approved medicine.